Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7619550 | 0.82 | KMT2A (0.57) | HPGDKMT2ATSHRALDH1A1 | |
| SCHEMBL4932875 | 0.77 | HPGD (0.50) | HPGDUSP2HSD17B10KMT2ATSHR | |
| SCHEMBL8333942 | 0.77 | LMNA (0.46) | HPGDUSP2HSD17B10KMT2ATSHR | |
| SCHEMBL16395235 | 0.76 | FKBP1A (0.43) | HPGDUSP2HSD17B10FKBP1A | |
| SCHEMBL3084451 | 0.76 | PKM (0.37) | KMT2AALDH1A1 | |
| SCHEMBL27807030 | 0.76 | OPRM1 (0.57) | KMT2AOPRM1OPRK1OPRD1 | |
| SCHEMBL8338883 | 0.76 | KMT2A (0.50) | HPGDUSP2HSD17B10KMT2ATSHR | |
| SCHEMBL16394945 | 0.76 | HPGD (0.39) | HPGDUSP2HSD17B10KMT2AFKBP1A | |
| SCHEMBL16395203 | 0.75 | FKBP1A (0.43) | KMT2ATSHRFKBP1AOPRM1 | |
| SCHEMBL9309031 | 0.75 | KMT2A (0.61) | HPGDKMT2ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | HPGD 423/4885USP2 3849/4885HSD17B10 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.